BioTuesdays Feature Articles | Life Sciences News

Feature

bioAffinity rolling out CyPath for early detection of lung cancer

bioAffinity Technologies (NASDAQ:BIAF) is rolling out CyPath Lung, an accurate, non-invasive and cost-effective test for the early detection of lung cancer, in the U.S. Southwest before a staged nationwide launch.

March 14, 2023

Feature

AUM Biosciences focused on reversing cancer resistance

With two clinical and two preclinical assets, AUM Biosciences is developing precision oncology therapeutics designed to reverse cancer resistance through multi-targeting approaches.

February 28, 2023

Feature

Cognition Therapeutics focused on modifying degenerative disorders

As the recipient of more than $170-million of non-dilutive grant funding, Cognition Therapeutics (NASDAQ:CGTX) is developing disease-modifying medicines for neurodegenerative disorders, such as Alzheimer's disease (AD)...

February 21, 2023

Feature

Context Therapeutics advancing pipeline for female cancers and other tumors

Martin Lehr likes to use a baseball analogy to describe his company’s two cancer programs. “CTIM-76 is our hot young rookie with home run potential at every bat while ONA-XR is our veteran who consistently gets on...

February 14, 2023

Feature

Indaptus advancing Decoy20 against metastatic solid tumors

Indaptus Therapeutics (NASDAQ:INDP) is conducting a first-in-human, dose escalation Phase 1 study of its lead compound, Decoy20, in patients with advanced metastatic solid tumors where currently approved therapies have...

February 7, 2023

Feature

Stephanie Willerth talks up award winning bioink start-up

As CEO and co-founder of closely-held Axolotl Biosciences, Stephanie Willerth, Ph.D., also is a full professor of biomedical engineering at the University of Victoria, British Columbia, where she runs a research lab...

January 31, 2023

Feature

Azura targeting ophthalmic keratolytics for ocular surface diseases

After posting positive Phase 2b results in November, Azura Ophthalmics plans to launch a Phase 3 registration trial in mid-2023 with its lead ointment, AZR-MD-001, for the treatment of meibomian gland dysfunction (MGD)...

January 24, 2023

Feature

Reneo targeting rare genetic mitochondrial diseases with unmet need

Reneo Pharmaceuticals (NASDAQ:RPHM) is conducting a pivotal Phase 2b clinical trial with its lead asset, REN001, in a rare genetic disease that predominately affects skeletal muscle and reduces life expectancy, with...

January 17, 2023

Feature

Theralase advances pivotal clinical study of photo dynamic therapy to treat bladder cancer

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) expects to complete enrollment and primary study treatment in early 2024 of a Phase 2 pivotal clinical study for non-muscle invasive bladder cancer (NMIBC) with its light...

January 3, 2023

Feature

OcuTerra advancing eye drop for earlier treatment of diabetic retinopathy

Closely-held OcuTerra Therapeutics is conducting a Phase 2 clinical study of a novel eye drop for earlier, non-invasive treatment of patients with moderate-to-severe diabetic retinopathy to preserve vision.

December 13, 2022

Feature

Avidity Biosciences developing new class of RNA therapeutics

Avidity Biosciences (NASDAQ:RNA) is developing a novel approach for the delivery of RNA therapeutics with a new class, known as antibody oligonucleotide conjugates (AOCs), with an initial focus on skeletal muscle...

December 6, 2022

Feature

Bolt pioneering new approach to cancer immunotherapy

Bolt Biotherapeutics (NASDAQ:BOLT) is developing tumor-targeting therapies that leverage the power of basic components of the innate and adaptive immune systems to attack the tumor microenvironment.

November 29, 2022

Feature

Kinaset developing dry powder inhalation therapy for severe asthma

Closely-held Kinaset Therapeutics is developing a less invasive and potentially more cost-effective dry power inhalation alternative to currently approved injectable biologicals used in the treatment of severe asthma.

November 22, 2022

Feature

MAIA telomere-targeting technology aiming at therapy-resistant tumors

MAIA Biotechnology (NYSE American:MAIA) is developing a telomere-targeting immunotherapy, THIO, with a dual mechanism of action, that can be used in sequential combination with existing immune therapies to target cancer.

November 15, 2022

Feature

Miromatrix bioengineering human organs to eliminate waitlists

With the need for organs for transplantation far exceeding the supply and creating long waitlists, Miromatrix Medical (NASDAQ:MIRO) is bioengineering human organs with the potential to eliminate the transplant waitlists.

November 8, 2022

Feature

Comera working to transform biologics to SQ injections from IV delivery

Comera Life Sciences (NASDAQ:CMRA) is using a proprietary excipient formulation platform, known as SQore, to potentially transform intravenous (IV) biologics into subcutaneous (SQ) versions that patients can self...

November 1, 2022

Feature

Atossa Therapeutics pivots inhalation therapy from COVID-19 to oncology

With widespread availability of SARS-CoV-2 vaccines and other therapies now approved to treat COVID-19, Atossa Therapeutics (NASDAQ:ATOS) has pivoted development of its AT-H201 inhalation therapy to cancer patients with...

October 25, 2022

Feature

OpSens SavvyWire tackling cardiology with advanced optical devices

With last month’s FDA clearance of the SavvyWire transcatheter aortic valve replacement (TAVR) guidewire, OpSens (TSX:OPS; OTCQX:OPSSF) is bringing a new concept to interventional cardiology and the delivery of new...

October 18, 2022

Feature

VoxNeuro is giving the brain a voice through cognitive health assessment

VoxNeuro’s software as a medical device (SaMD) is transforming cognitive health assessment as it pushes the boundaries of our understanding of the brain to improve decision-making by clinicians and patients.

October 11, 2022

Feature

Sigyn Therapeutics outlines first-in-human clinical strategy for its novel blood purification technology

Sigyn Therapeutics (OTCQB:SIGY) has transitioned its Sigyn Therapy blood-purification device from conceptual design two years ago to preparing to initiate its first-in-human studies in end-stage renal disease patients...

October 4, 2022

Feature

Kiora Pharma eyes novel approach to vision restoration in retinitis pigmentosa

Kiora Pharmaceuticals (NASDAQ:KPRX) expects to release Phase 1b interim data at the beginning of 2023 from its flagship intravitreal injection to potentially restore vision in patients with retinitis pigmentosa, a rare...

September 27, 2022

Feature

Blue Water Vaccines designing vaccines against infectious diseases

Blue Water Vaccines (NASDAQ:BWV) is building an early-stage pipeline of six transformational vaccine candidates targeting important infectious diseases, including inner ear infections, influenza, norovirus, rotavirus...

September 20, 2022

Subscribe